Next Article in Journal
Evaluation of Tissue and Circulating miR-21 as Potential Biomarker of Response to Chemoradiotherapy in Rectal Cancer
Next Article in Special Issue
Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma
Previous Article in Journal
Role of Chronic Lymphocytic Leukemia (CLL)-Derived Exosomes in Tumor Progression and Survival
Review

Antibody–Drug Conjugates: The Last Decade

1
GICC EA7501, Equipe IMT, Université de Tours, UFR des Sciences Pharmaceutiques, 31 Avenue Monge, 37200 Tours, France
2
Institut de Recherche Pierre Fabre, Centre d’Immunologie Pierre Fabre, 5 Avenue Napoléon III, 74160 Saint Julien en Genevois, France
3
Cancer Research Center of Lyon (CRCL), INSERM, 1052/CNRS 5286/UCBL, 69000 Lyon, France
4
Hospices Civils de Lyon, 69000 Lyon, France
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(9), 245; https://0-doi-org.brum.beds.ac.uk/10.3390/ph13090245
Received: 17 August 2020 / Revised: 7 September 2020 / Accepted: 10 September 2020 / Published: 14 September 2020
(This article belongs to the Special Issue Antibody-Drug Conjugates (ADC): 2021)
An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylotarg®) was used clinically, in 2020, 9 Food and Drug Administration (FDA)-approved ADCs are available, and more than 80 others are in active clinical studies. This review will focus on FDA-approved and late-stage ADCs, their limitations including their toxicity and associated resistance mechanisms, as well as new emerging strategies to address these issues and attempt to widen their therapeutic window. Finally, we will discuss their combination with conventional chemotherapy or checkpoint inhibitors, and their design for applications beyond oncology, to make ADCs the magic bullet that Paul Ehrlich dreamed of. View Full-Text
Keywords: antibody–drug conjugate; ADC; bioconjugation; linker; payload; cancer; resistance; combination therapies antibody–drug conjugate; ADC; bioconjugation; linker; payload; cancer; resistance; combination therapies
Show Figures

Graphical abstract

MDPI and ACS Style

Joubert, N.; Beck, A.; Dumontet, C.; Denevault-Sabourin, C. Antibody–Drug Conjugates: The Last Decade. Pharmaceuticals 2020, 13, 245. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13090245

AMA Style

Joubert N, Beck A, Dumontet C, Denevault-Sabourin C. Antibody–Drug Conjugates: The Last Decade. Pharmaceuticals. 2020; 13(9):245. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13090245

Chicago/Turabian Style

Joubert, Nicolas, Alain Beck, Charles Dumontet, and Caroline Denevault-Sabourin. 2020. "Antibody–Drug Conjugates: The Last Decade" Pharmaceuticals 13, no. 9: 245. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13090245

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop